Thrombogenics Awarded €1.1 million IWT Research Grant
Dr Patrik De Haes, CEO of ThromboGenics comments: “The award of this grant from IWT supports our commitment to gain further insight into JETREA®s action in the vitreo-retinal interface. In conjunction with a growing body of real world and clinical trial data, we hope that the continual efforts at the preclinical research level will contribute to an improved awareness and acceptance of JETREA® by physicians as a first in class pharmaceutical treatment for symptomatic VMA.”
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.